The origins of adult-onset diabetes

R. David Leslie & Tanwi Vartak

Published online: 7 December 2019
© The Author(s) 2019

Abstract
Physiological plasticity enables homeostasis to be maintained in biological systems, but when such allostasis fails, then disease can develop. In a new population-based study by Rolandsson et al. (https://doi.org/10.1007/s00125-019-05016-3), autoimmunity, defined by an immunogenotype, predicted adult-onset non-insulin requiring diabetes. Type 1 diabetes is no longer viewed as a disease confined to children, with a significant proportion, maybe the majority, presenting in adulthood. Such cases masquerade as type 2 diabetes and their identification has clinical utility. Nevertheless, in this study, autoimmunity had a limited effect on the overall risk of adults developing diabetes.

Keywords Autoantibodies · Autoimmunity · C-peptide · Diabetes · Diabetes heterogeneity · Diabetes risk · Genetics

Abbreviations
EPIC European Prospective Investigation into Cancer and Nutrition
GADA GAD65 autoantibodies
GRS Genetic risk score
HUNT Nord-Trøndelag Health Study
LADA Latent autoimmune diabetes in adults

Epidemics in the 19th century were, in the main, due to infectious diseases; diabetes was different. In 1888 Etienne Lancereaux, a French physician, believed that individuals with diabetes were either thin (‘maigre’) or fat (‘gras’) [1]. More precisely, the latter were invariably rich and fat. Adult-onset diabetes was considered a disease of civilisation, secondary to poor digestion and bad nerves, but a homogeneous disease, nonetheless, with a homogeneous outcome. In contrast people with ‘diabete maigre’ were invariably thin, young, desperately ill and, within a year, dead. The introduction of insulin in 1921 commuted the death sentence to a life sentence but emphasised that self-evident distinction between the insulin-dependent form of diabetes and everything else, then called non-insulin-dependent diabetes, now type 2 diabetes. Ascribing the modern global epidemic of adult-onset diabetes to a maladaptation to civilisation did not, until recently, alter the perspective that the disease could be lumped under one umbrella with a common pathogenesis and uniform therapeutic pathway.

Diabetes as a binary disease
That binary perspective of diabetes changed as we engaged with maturity onset diabetes of the young (MODY) and adult-onset autoimmune diabetes, also called latent autoimmune diabetes in adults (LADA) [2]. Awareness that the patient in front of you, young or old, lean or fat, could have different forms of diabetes, has pushed physicians away from simple clinical assessment into the realm of precision medicine. For the patient with adult-onset diabetes, three features, aside from demographics, have provided traction in dissecting the nature of this disease process: genetics, including genetic risk scores (GRS); immunology, in the form of diabetes autoantibodies, including autoantibodies to GAD65 (GADA), and serum C-peptide as a proxy for insulin secretion (Fig. 1) [2, 3].

GADA and GRS predicts adult-onset diabetes

In this issue of Diabetologia, Rolandsson and colleagues have leveraged two of these three markers, i.e. GADA and GRS, in a population-based study of individuals (over 340,000 individuals)
participants over 40 years of age and free of known diabetes at baseline), followed for 10 years to determine the potential for these markers to identify those at risk of diabetes [4]. For those with GADA initially, there was indeed an increased risk that diabetes would develop during follow-up (HR 1.78 for GADA positive vs GADA negative). Moreover, the GRS for type 1 diabetes, but not for type 2 diabetes, was associated with GADA in incident cases (OR 1.97) (Fig. 2). The GRS was calculated by multiplying the number of disease risk-increasing gene alleles by the natural log of OR at each locus, then summing these ORs for each individual. This risk for developing diabetes in the EPIC cohort was further increased to 3.2 by combining GADA positivity with the top tertile of type 1 diabetes risk according to the GRS (Fig. 2). The authors, in concluding that incident adult-onset diabetes has an element of autoimmunity, proposed that the present subclassification of diabetes in adulthood should be re-evaluated.

In one sense, we could have anticipated these results. GADA are known to appear largely within the first decade of life and predict diabetes in children [5]. However, there have only been a couple of previous similar prospective studies reporting that GADA predicted adult-onset diabetes. In the Botnia Study, GADA (vs no GADA) predicted non-insulin-requiring diabetes (HR 4.9) [6], while in the Nord-Trøndelag Health Study (HUNT), even evanescent GADA predicted diabetes and these diabetes patients tended to be younger, with lower C-peptide and higher HbA1c [7, 8]. As illustrated by this present large study from EPIC, the percentage with GADA was small, and so the percentage with GADA who developed diabetes was small. It seems reasonable to conclude from these studies that autoimmunity does not play a major role in the development of adult-onset diabetes among older adults. Certainly, in population-based studies of adults with diabetes the frequency of GADA is low, as with this present European study, while in clinic-based studies, that GADA frequency tends to be 5–10%, whether in China or Europe [4, 9–11]. Prospective data from HUNT indicated that incident diabetes cases, who were overweight with a family history of diabetes plus GADA positivity, as compared with GADA negative cases, had an OR for diabetes risk of 7.5. By implication, GADA positivity in the general population identifies a small number at risk of late adult-onset autoimmune diseases, that is thyroid autoimmunity and diabetes [12]. For diabetes this risk is higher in overweight individuals with both a family history of diabetes and high GRS for type 1 diabetes.

**Disease identity and uncertainty**

At the heart of this discussion is the issue of disease identity. Few common diseases are clinically homogeneous; most show a continuum of clinical changes. Autoimmune diseases are no exception. Type 1 diabetes is also a heterogeneous condition with diverse immunogenetic characteristics and clinical outcomes [2]. This clinical and immunogenetic heterogeneity extends from childhood-onset autoimmune diabetes into adult-onset autoimmune diseases, including people presenting who do not need insulin therapy [3]. It used to be argued that non-insulin-requiring adult-onset autoimmune diabetes either did not exist or was classic type 1 diabetes caught fleetingly in progression before insulin treatment was required, which would contrast with the clinical spectrum in Hashimoto’s thyroiditis. This argument was based on the specificity of the GADA assay when applied to a general population; in which case a substantial fraction of GADA positive cases would be false
positives. But the argument does not extend to positive predictive values, which can be altered by reconfiguring cut-off points in specific cohorts, enriching the cohort for clinical features such as adult-onset diabetes, even altering the assay itself [10, 13]. Nor would it explain the predominance of GADA in all adult-onset diabetes cohorts when other diabetes-associated autoantibodies can be detected, but at far lower frequency, or the marked drop in GADA positivity with increasing age at diagnosis in adults [14]. Nevertheless, there will be a false-positive rate, even with the state-of-the-art GADA assay employed by Rolandsson et al [4], plus an unquantified, likely low, false-negative rate. GADA can be transient and, while invariably predominant, do consistently underestimate the percentage of diabetes cases with diabetes-associated autoantibodies e.g. in a clinic-based adult diabetes cohort, diabetes-associated autoantibodies other than GADA detected an additional 7.3% of autoimmune cases [9, 10]. By implication, there will be a small number of additional individuals with other diabetes-associated autoantibodies that were not assayed.

Disease risk, scale and certainty

To support the argument that this cohort of adult-onset autoimmune diabetes cases have type 1 diabetes they should have the type 1 diabetes-associated genetic risk including histocompatibility antigen (HLA)-associated risk. Major studies from Europe and China have shown just that [15, 16]. A large European cohort of individuals with LADA who were not treated with insulin at diagnosis showed four genetic signals that achieved genome-wide significance at established type 1 diabetes risk loci (HLA, PTPN22, INS and SH2B3) [16]. Indeed, these same four loci were identified in a major Chinese study of individuals with adult-onset type 1 diabetes who were treated with insulin from diagnosis [15]. Despite strong genetic correlations across the whole age range, childhood-onset type 1 diabetes shows a greater genetic load than adult-onset type 1 diabetes, consistent with higher GRS and higher disease concordance rates in twins with childhood-onset diabetes [17]. By implication, a GRS derived from childhood-onset type 1 diabetes will underestimate the numbers of cases with type 1 diabetes genetic risk if applied to an adult cohort [18]. This underestimation, together with the likely reduced sensitivity for GADA using this highly specific GADA assay and the likely failure to identify all autoimmune cases as only GADA were tested means that the actual numbers of autoimmune cases will probably be higher than estimated. That said, attributable risk in this population of adult-onset diabetes with GADA is very low at 1.8%, so even a substantial error would have little impact on the overall risk of autoimmune diabetes in adults aged over 40 years [4]. However, the risk of GADA-positive cases developing autoimmune diabetes would likely be much higher in younger adults, as autoimmune diabetes is more prevalent in this age group than in older adults.

Rolandsson et al emphasise the importance of scale in their data and the notion that autoimmune damage could contribute to the development of adult-onset diabetes, whether defined clinically as insulin dependent or non-insulin dependent [4]. Certainly, individuals with adult-onset diabetes who have a high type 1 diabetes GRS and high-titre GADA are at risk of progressing to insulin dependence [19]. This risk falls as the GRS falls [20]. C-peptide levels vary across the age range and with disease duration, even for individuals diagnosed clinically and immunologically with type 1 diabetes (Fig. 1) [21]. Older GADA-positive patients, as studied here, with moderate GRS for type 1 diabetes may clinically resemble patients with type 2 diabetes in that they could have substantial C-peptide. A prospective study of C-peptide in older low-titre GADA-positive Chinese patients (vs high titre) revealed a natural history indistinguishable from type 2 diabetes over a number of years [22]. In a large Chinese population-based adult cohort, ascertained from a notably younger age than in the present study (i.e. over 20 years), the standardised prevalence rate of autoimmune diabetes was 6.0% in adults with diabetes who did not initially require insulin, which corresponds to six million adults in China with a form of autoimmune diabetes that is initially non-insulin requiring [9].

Allostasis and tipping points

As insulin secretory capacity is compromised, perhaps by an autoimmune process, so pathways that maintain glucose homeostasis and glucose disposition should adjust the levels of insulin secretion to insulin sensitivity. Allostasis, the ability to adapt to maintain glucose homeostasis, must be compromised for this homeostasis to be lost with ensuing dysglycaemia. Taken together, the present data can be viewed from a dual perspective. On one hand, elements of type 2 diabetes might have an autoimmune basis and from that perspective the authors call for a re-evaluation of the present sub-classification of diabetes in adulthood. The problem with type 2 diabetes is that it lacks a biomarker and is effectively a diagnosis of exclusion [2, 3]. Furthermore, the GRS for type 2 diabetes is in general very low and many thousands of patients need to be studied to define differences from a ‘normal’ population. Quite what constitutes a ‘normal’ population is another matter, given the widespread predisposition to dysglycaemia with age. If these GADA-positive autoimmune cases have a form of type 2 diabetes, then they would be expected to have an increased BMI and waist hip ratio, whereas the converse is true (Fig. 2) [4]. From another perspective, the data could be seen to validate the hypothesis that autoimmune diabetes is a spectrum ranging from childhood-onset type 1 diabetes to adult-onset non-insulin-dependent diabetes masquerading as type 2 diabetes [2]. Certainly, the higher GRS for type 1 diabetes and leaner habitus of the GADA-positive individuals is
consistent with this proposal (Fig. 2) [4]. Either way, the argument is not futile as there is clinical utility in the identification of autoimmune diabetes. Such patients tend to have a more dynamic clinical history requiring more frequent clinical review. In addition, they should probably not be treated with sulfonylureas, they should be investigated for other forms of autoimmunity and they are at particular risk of hyperglycaemia and progression to insulin therapy [2, 23–25].

In short, the autoimmune process is associated with diabetes, but that risk is a continuum, just as glucose and glucose disposition, insulin secretion and insulin sensitivity represent continua. For the physician, biomarkers are merely guides to management but will surely help a more nuanced approach to the patient sitting in front of you.

**Acknowledgements** We thank Lorenzo Campioni, Roberta Iannuzzi, Meleri Jones and Polychronis Kemos (Blizard Institute, London, UK) with their help in drawing the Figures.

**Funding** The authors are funded by EFSD (grant ref. 970009) (RDL, TV), Diabetes UK (grant ref. 15/0005232) (RDL) and Diabetic Twin Trust (RDL).

**Duality of interest** The authors declare that there is no duality of interest associated with this manuscript.

**Contribution statement** Both authors were responsible for drafting the article and revising it critically for important intellectual content. Both authors approved the version to be published.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Lancereaux E (1877) Note et réflexions sur deux cas de diabète sucré avec altération du pancréas. Bull Acad Méd 2e serie, tom VI, pp 1215 (in French)
2. Leslie RD, Palmer J, Schloot NC, Lemmark A (2016) Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. Diabetologia 59(1):13–20. https://doi.org/10.1007/s00125-015-3789-z
3. Ahlqvist E, Storm P, Käräjämäki A et al (2018) Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 6(5):361–369. https://doi.org/10.1016/S2213-8587(18)30051-2
4. Rollandsson O, Hampe C, Sharp S et al (2019) Autoimmunity plays a role in the onset of diabetes after 40 years of age. Diabetologia https://doi.org/10.1007/s00125-019-05016-3
5. Ziegler AG, Rewers M, Simell O et al (2013) Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309(23):2473–2479. https://doi.org/10.1001/jama.2013.6285
6. Lundgren VM, Isomaa B, Lyssenko V et al (2010) GAD antibody positivity predicts type 2 diabetes in an adult population. Diabetes 59(2):416–422
7. Sørgjerd EP, Thorøy PM, Torjesen PA, Skorpen F, Kvaløy K, Grill V (2015) Presence of anti-GAD in a non-diabetic population of adults; time dynamics and clinical influence: results from the HUNT study. BJM Open Diab Res Care 3(1):e000076. https://doi.org/10.1136/bmjdr-2014-000076
8. Sørgjerd EP, Asvold BO, Thorøy PM, Grill V (2018) Individuals fulfilling criteria for type 2 diabetes rather than LADA display transient signs of autoimmunity preceding diagnosis with possible clinical implications: The HUNT Study. Die Care 41(12):e161–e163
9. Xiang Y, Huang G, Zhu Y et al (2019) Identification of autoimmune type 1 diabetes and multiple organ-specific autoantibodies in adult-onset non-insulin-requiring diabetes in China: a population-based multicentre nationwide study. Diabetes Obes Metab 21(4):893–902
10. Hwa MI, Kolb H, Schloot N et al (2013) Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: action LADA 7. Diabetes Care 36(4):908–913
11. Zhou Z, Xiang Y, Ji L et al (2013) Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China Study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes 62(2):543–550. https://doi.org/10.2337/db12-0207
12. Hjort R, Ahlqvist E, Carlsson P-O et al (2018) Overweight, obesity and the risk of LADA: results from a Swedish case–control study and the Norwegian HUNT Study. Diabetologia 61(6):1333–1343. https://doi.org/10.1007/s00125-018-4596-0
13. Achenbach P, Hwa MI et al (2018) Autoantibodies to N-terminally truncated GAD improve clinical phenotyping of individuals with adult-onset diabetes: Action LADA 12. Diabetologia 61(7):1644–1649
14. Turner R, Stratton I, Horton V et al (1997) UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. Lancet 350(9087):1288–1293
15. Zhu M, Xu K, Chen Y et al (2019) Identification of novel T1D risk loci and their association with age and islet function at diagnosis in autoantibody-positive T1D Individuals: based on a two-stage genome-wide association study. Diabetes Care 42(8):1414–1421. https://doi.org/10.2337/dc18-2023
16. Cousminier DL, Ahlqvist E, Mishra R et al (2018) First genome-wide association study of latent autoimmune diabetes in adults reveals novel insights linking immune and metabolic disease. Diabetes Care 41(11):2396–2403
17. Redondo MJ, Yu L, Hwa M et al (2001) Heterogeneity of type 1 diabetes: analysis of monozygotic twins in Great Britain and the United States. Diabetologia 44(3):354–362. https://doi.org/10.1007/s001250051626
18. Thomas NJ, Lynam AL, Hill AV et al (2019) Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes. Diabetologia 62(7):1167–1172. https://doi.org/10.1007/s00125-019-4863-8
19. Grubb AL, McDonald TJ, Rutters F et al (2019) A type 1 diabetes genetic risk score can identify patients with GAD65 autoantibody-positive type 2 diabetes who rapidly progress to insulin therapy. Diabetes Care 42(2):208–214. https://doi.org/10.2337/dc18-0431
20. Howson JMM, Rosinger S, Smyth DJ, Boehm BO, the ADBW-END Study Group, Todd JA (2011) Genetic analysis of adult-onset autoimmune diabetes. Diabetes 60(10):2645–2653. https://doi.org/10.2337/db11-0364
21. McKeigue P, Spiliopoulou A, McGurnaghan S et al (2019) Persistent C-peptide secretion in type 1 diabetes and its relationship
22. Liu L, Li X, Xiang Y, Huang G et al (2015) Latent autoimmune diabetes in adults with low-titer GAD antibodies: similar disease progression with type 2 diabetes: a nationwide, multicenter prospective study (LADA China Study 3). Diabetes Care 38(1):16–21. https://doi.org/10.2337/dc14-1770

23. Hals IK, Fiskvik Fleiner H et al (2019) Investigating optimal β-cell-preserving treatment in latent autoimmune diabetes in adults: Results from a 21-month randomized trial. Diabetes Obes Metab 21(10):2219–2227. https://doi.org/10.1111/dom.13797

24. Maruyama T, Tanaka S, Shimada A et al (2008) Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 93(6):2115–2121

25. Lynam A, McDonald T, Hill A et al (2019) Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18-50 years. BMJ Open 9(9):e031586. https://doi.org/10.1136/bmjopen-2019-031586

Publisher’s note  Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.